Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - Jasper Therapeutics is advancing briquilimab, a novel antibody therapy targeting mast cell-driven diseases, with significant progress reported in clinical trials [2][5][7] - The company reported a net loss of $21.2 million for the first quarter of 2025, with a basic and diluted net loss per share of $1.41 [6][10] Clinical Development - Jasper is focused on three clinical programs: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, with important data readouts expected later in 2025 [2][5] - The BEACON study in CSU continues to show promising results, with updated data presented at major allergy meetings [2][5] - Enrollment in the BEACON Phase 1b/2a study is ongoing, with additional data expected in Q3 2025 [5] - The SPOTLIGHT study for CIndU has completed enrollment in its final cohort, with data presentation planned for June 2025 [5] - The ETESIAN study for asthma is also enrolling patients, with initial data anticipated in the second half of 2025 [5] Financial Performance - As of March 31, 2025, Jasper had cash and cash equivalents totaling $48.8 million, down from $71.6 million at the end of 2024 [5][12] - Research and development expenses for Q1 2025 were $16.2 million, while general and administrative expenses were $5.6 million [5][10] - Total operating expenses for the first quarter were $21.8 million, compared to $15.1 million in the same period of 2024 [10]